Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, Barnaby Young, Jacqueline Nordwall, Sanjay Bhagani, Po-Ying Chia, Ruby Davis, Clark Files, Adit A Ginde, Timothy Hatlen, Marie Helleberg, Awori Hayanga, Tomas O Jensen, Mamta K Jain, Ioannis Kalomenidis, Kami Kim, Perrine Lallemand, Birgitte Lindegaard, Anupama Menon, Katherine Ognenovska, Garyfallia Poulakou, Birgit Thorup Røge, Angela J Rogers, Katy Shaw-Saliba, Uriel Sandkovsky, Barbara W Trautner, Shikha S Vasudeva, Andrew Vekstein, Kimberley Viens, James Wyncoll, Brian DuChateau, Zhenxing Zhang, Shujiang Wu, Abdel G Babiker, Victoria Davey, Annetine Gelijns, Elizabeth Higgs, Virginia Kan, Jens Lundgren, Gail V Matthews, H Cliff Lane
BACKGROUND: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests. METHODS: COVID-19 inpatients were recruited to evaluate 2 POC tests: LumiraDX and RightSign. Ease of use data was collected. Blood was also collected for centralized testing using established antibody assays (GenScript cPass). A nested case-control study assessed if POC tests conducted on stored specimens were predictive of time to sustained recovery, mortality, and a composite safety outcome...
September 12, 2024: Journal of Infectious Diseases